HETEROCYCLIZATION REACTION OF ANTHRANILIC ACID WITH ALLYL ISOCYANATE

Zulpanov F. A., Juraev B. B., Abdimurativa Z. E., Ashirmatova N. M. & Elmuradov B. J.


Annotatsiya

By synthesizing compounds containing various functional groups within the heterocyclic structure, optimal reaction conditions were proposed. To optimize the reaction parameters, a series of experiments were carried out, in which factors such as the type of solvent (DMF, DMSO), the nature of the main heterocyclizing reagent (substituted isocyanates, substituted isothiocyanates), temperature, and reaction time were studied. Among the synthesized compounds, promising samples with high biological activity were identified. It was established that the proposed synthesis method is relatively simple and cost-effective. The structures of the synthesized benzyl derivatives were confirmed using modern physicochemical methods (IR and NMR spectroscopy).


Adabiyotlar

  1. 1.Wu X., Li M., Tang W., Zheng Y., Lian J., Xu L., Ji M. Design Synthesis and In vitro Antitumor Activity Evaluation of Novel 4-pyrrylamino Quinazoline Derivatives. Chemical biology & drug design. 2011;78(6):932-940 p.
  2. Singh K, Sharma P, Kumar A, Chaudhary A, Roy R. 4Aminoquinazoline Analogs: A Novel Class of Anticancer Agents. Mini reviews in medicinal chemistry. 2013;13(8):1177-1194
  3. Marzaro G, Guiotto A, Chilin A. Quinazoline derivatives as potential anticancer agents: a patent review (2007-2010). Expert opinion on therapeutic patents. 2012;22-23 p.
  4. Mikra C., Bairaktari M., petridi M., Detsi A. Issue 10. 2022. 20-21 p. doi.org 10.3390 p.
  5. Wang S.B., Deng X.Q., Zheng Y., Yuan Y.P., Quan Z.S., Guan L.P. Synthesis and evaluation of anticonvulsant and antidepressant activities of 5alkoxytetrazolo[1,5-c]thieno[2,3e]pyrimidine derivatives. European journal of medicinal chemistry. 2012;56:139-144 p.
  6. Sordella R., Bell D.W., Haber D.A. and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. - 2004. -Vol. 305. - 1163-1167 p.
  7. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., Pazdur R. (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist; 10:461–466 p.
  8. Pawan K., Premnath D., Muhammad T., Mazlee S., Yaman M., Nurul S., Muhammad S. et al. A controlled, efficient and robust process for the synthesis of an epidermal growth factor receptor inhibitor: Afatinib Dimaleate. February 4, 2019. 5-105-106 p. DOI:10.25082/CR.2019.01.001
  9. Petrov K.G., Zhang Y.M., Carter M., Cockerill G.S., Dickerson S., Gauthier C.A., Guo Y., Mook R.A. Jr, Rusnak D.W., Walker A.L., Wood E.R., Lackey K.E. (2006) Optimization and SAR for dual ErbB-1 ⁄ ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg Med Chem Lett; 16:4686–4691.
  10. Wu X., Li M., Qu Y., Tang W., Zheng Y., Lian J., Ji M., Xu L. (2010) Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg Med Chem; 18:3812–3822 p.
  11. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur RFDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist; 8: (2003) 303–306 p.